New Ventures in RNAi

There are many new therapeutic frontiers for our RNA technology, including applications in vaccine development, stem cell biology, bio-processing, genomics and biologics. We will continue to "innovate within innovation" and pursue these new high-value opportunities.

We have already created a new company for microRNA therapeutics, Regulus Therapeutics. microRNAs are small RNAs that exist naturally within mammalian cells and are believed to regulate the expression of over one-third of all human genes in the genome. They have been implicated in cancer, metabolic disease, viral infection, and immune disease, and we are excited about the potential for microRNA therapeutics that address entire pathways of disease.

Alnylam's Ventures

Regulus Therapeutics Inc.

In 2007, Alnylam and Isis created Regulus, the leading microRNA therapeutics company. Isis and Alnylam scientists and collaborators were the first to discover microRNA antagonist strategies that work in vitro and in vivo in animal studies (Krutzfeldt et al. (2005) Nature 438, 685-689; Esau et al. (2006) Cell Metab., 3, 87-98). Isis and Alnylam have also created and consolidated key IP believed by the companies to be required for development and commercialization of microRNA therapeutics. The company is based in Carlsbad, California. For more information, visit www.regulusrx.com.